 |
|
|
| |
Metabolism, Excretion, and Mass Balance of the HIV Integrase Inhibitor, Cabotegravir (GSK1265744) in Humans
|
| |
| |
Reported by Jules Levin
ICAAC - 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC
A Culp,1 G Bowers,1 E Gould,1 S Ford,1 Y Lou,1 R Pan,2 D Margolis,1 S Piscitelli1
1GlaxoSmithKline, Research Triangle Park, NC; 2GlaxoSmithKline, Collegeville, PA
ICAAC: Cabotegravir Injected Every 1, 2, or 3 Months Yields Adequate Troughs in Simulation
|
| |
|
|
|
|
|
